Ryan Faulkingham
Analyst · Leslie Vandegrift from Raymond James
Yes, sure. So there's really three aspects to the new tax legislation that impacts our subsidiaries. Of course, domestically. We all, or some of our businesses have international operations. So there are taxes we pay foreign, so those will continue as they are. But on the domestic side, of course we've got the rate deduction -- reduction -- from 35% to 21%, which is a real nice benefit to our companies at our C corporations, especially those that are taxpayers. Of course, some of our companies are not taxpayers. Some of our companies, too, that are recently purchased who have tax assets are also not taxpayers. So it helps a few of them, but not all. In addition, there's the ability to accelerate the deduction of CapEx spend which, interestingly, began in September, so some of our companies took advantage of that in Q4, but that will be a nice cash flow tailwind in '18. And offsetting that, of course, is this interest deduction limitations. And that, again, affects only, I believe, 2 of our companies with respect to that. But interestingly, those are also the companies that have higher CapEx spends. So they'll have the benefit of that accelerating the deductibility of that CapEx spend. So net-net, it is very positive to the companies. In terms of modeling and how to think about it, historically if you went back the past few years, our cash taxes as a percentage of our consolidated subsidiary EBITDA has been between 13% and 15%. And interestingly, 2017 was very low. It was, I think, a little bit above 9%, and that's a function of some unique circumstances. One is, of course, some companies took advantage of that accelerated CapEx spend, which I mentioned. But also, one of our subsidiaries had a significant R&D tax credit study done and paid virtually no tax in 2017. So pushing '17 aside as a very unique year, I think going forward, that range, you can expect to be at least in '18, where we've got some visibility, between 10% and 12% of consolidated subsidiary EBITDA. Okay, again, caveat being foreign tax impact is something that will continue as is without any of these benefits I mentioned. Does that help?